H(2) inhalation therapy in patients with moderate COVID-19 (H(2)COVID): a prospective ascending-dose phase I clinical trial
氢气吸入疗法治疗中度 COVID-19 患者(H₂COVID):一项前瞻性递增剂量 I 期临床试验
期刊:Antimicrobial Agents and Chemotherapy
影响因子:4.5
doi:10.1128/aac.00573-24
Salomez-Ihl, C; Giai, J; Barbado, M; Paris, A; Touati, S; Alcaraz, J P; Tanguy, S; Leroy, C; Lehmann, A; Degano, B; Gavard, M; Bedouch, P; Pavese, P; Moreau-Gaudry, A; Roustit, M; Boucher, F; Cinquin, P; Brion, J P